 Home > Medical News > Medicines Company News > Kangfang Bio-IL-4R monoclonal antibody was approved for clinical indication for moderate to severe atopic dermatitis

Kangfang Bio-IL-4R monoclonal antibody was approved for clinical indication for moderate to severe atopic dermatitis

 Last Update: 2021-05-02
 Source: Internet
 Author: User

Tags

herpes type 1

pcp drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 8, the CDE official website showed that Kangfang Biologics Class 1 new drug AK120 injection was approved for clinical use, and the indication is moderate to severe atopic dermatitis.

AK120 is a new type of autoimmune disease treatment drug that targets IL-4R independently developed by Kangfang Biology.

The world's first IL-4R monoclonal antibody is Dupixent jointly developed by Sanofi and Regeneron.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.